Literature DB >> 9795923

The natural course of chronic hepatitis C: implications for clinical practice.

G M Dusheiko1.   

Abstract

Hepatitis C is an important public health problem with high rates of chronic infection ensuing after viral acquisition. The spectrum of the disease ranges from mild to severe chronic hepatitis, cirrhosis and hepatocellular carcinoma. Extra-hepatic manifestations may occur. The disease is complex and predictions about long-term prognosis for individual patients remain difficult. It is generally accepted that 10-20% of patients with chronic hepatitis C will develop cirrhosis within 10 years of first infection: identifying the group of patients at greatest risk remains a primary challenge for clinicians. Older age of infection, duration of infection, degree of liver inflammation at first biopsy and cofactors such as alcohol abuse, all appear to be predictors of a poorer prognosis. The following paper aims to identify some of the features of the natural history of hepatitis C most relevant to the clinician.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795923     DOI: 10.1046/j.1365-2893.1998.0050s1009.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

3.  Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis.

Authors:  Dena L Schanzer; Dana Paquette; Lisa M Lix
Journal:  CMAJ Open       Date:  2014-07-22

4.  The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection.

Authors:  S Barrett; J Goh; B Coughlan; E Ryan; S Stewart; A Cockram; J C O'Keane; J Crowe
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

5.  IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

Authors:  Mayu Ohnishi; Masataka Tsuge; Tomohiko Kohno; Yizhou Zhang; Hiromi Abe; Hideyuki Hyogo; Yuki Kimura; Daiki Miki; Nobuhiko Hiraga; Michio Imamura; Shoichi Takahashi; Hidenori Ochi; C Nelson Hayes; Shinji Tanaka; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2012-02-18       Impact factor: 7.527

6.  Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Authors:  Eisuke Murakami; Michio Imamura; C Nelson Hayes; Hiromi Abe; Nobuhiko Hiraga; Yoji Honda; Atsushi Ono; Keiichi Kosaka; Tomokazu Kawaoka; Masataka Tsuge; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe.

Authors:  Nyasha Chin'ombe; Evans Chavhunduka; Hilda T Matarira
Journal:  Infect Agent Cancer       Date:  2009-10-08       Impact factor: 2.965

8.  Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.

Authors:  Zhongjie Hu; Ying Liu; Lixia Qiu; Zuopeng Fan; Wei Nie; Shan Liang; Ronghua Jin
Journal:  Virol J       Date:  2015-12-18       Impact factor: 4.099

9.  Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.

Authors:  Chao-Min Huang; Kuo-Chin Chang; Chao-Hung Hung; King-Wah Chiu; Sheng-Nan Lu; Jing-Houng Wang; Chien-Hung Chen; Kwong-Ming Kee; Yuan-Hung Kuo; Ming-Chao Tsai; Po-Lin Tseng; Ming-Tsung Lin; Cheng-Kun Wu; Tsung-Hui Hu; Chung-Lung Cho; Yi-Hao Yen
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.